公开(公告)号：US12257348B2

公开(公告)日：2025-03-25

申请号：US17327724

申请日：2021-05-23

Applicant: Sol-Gel Technologies Ltd.

Inventor： Ofer Toledano ,  Karine Neimann ,  Danil Finkel-Moiseev ,  Maya Erlich ,  Dorit Marco

IPC: A61K9/48 ,  A61K9/00 ,  A61K9/50 ,  A61K31/202 ,  A61K31/203 ,  A61K31/235 ,  A61K31/327 ,  A61K31/336

Abstract: The present application is directed to stabilized core-shell microcapsules comprising a core of benzoyl peroxide (BPO) or all trans retinoic acid (ATRA) and a metal-oxide shell; and to pharmaceutical compositions and methods of use thereof.

公开(公告)号：US11633399B2

公开(公告)日：2023-04-25

申请号：US16737503

申请日：2020-01-08

Applicant: SOL-GEL TECHNOLOGIES LTD.

Inventor： Moshe Arkin ,  Marcel Zighelboim ,  Ori Nov ,  Ofer Toledano ,  Karine Neimann

IPC: A61K31/505 ,  A61K31/517 ,  A61K31/5377 ,  A61K39/395 ,  A61K9/00 ,  A61K45/06 ,  A61K31/05 ,  A61K9/06 ,  A61K31/506

Abstract: This invention relates to compositions and methods of treatment of skin or mucosal disorders by administration of compositions comprising at least one EGFR inhibitor, such as topical compositions comprising erlotinib. The compositions of this invention are useful for the treatment, prevention or amelioration of skin or mucosal disorders like psoriasis, palmoplantar psoriasis, acquired palmoplantar keratosis, eczema, ichtyosis vulgaris, non-melanoma skin cancer, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, pachyonychia congenita, hidradenitis suppurativa, Gorlin syndrome, prurigo nodularis and prurigo pigmentosa.

公开(公告)号：US20210236432A1

公开(公告)日：2021-08-05

申请号：US17166336

申请日：2021-02-03

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe Arkin ,  Marcel Zighelboim ,  Karine Neimann ,  Hila Hakak Djerbi

IPC: A61K9/50 ,  A61K31/44 ,  A61K9/06

Abstract: Provided herein is a topical composition comprising roflumilast, roflumilast N-oxide or salts thereof as an active agent. The active agent in the composition of this invention is in encapsulated or non-encapsulated form, according to need.
The above composition is useful for the treatment, prevention or alleviation of a skin disorder selected from Hidradenitis suppurativa and Prurigo nodularis.

公开(公告)号：US20230346716A1

公开(公告)日：2023-11-02

申请号：US18350513

申请日：2023-07-11

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe ARKIN ,  Danil Finkel-Moiseev ,  Hila Hakak Djerbi ,  Karine Neimann

IPC: A61K31/05 ,  A61K9/06 ,  A61K47/44 ,  A61K47/10 ,  A61K47/18 ,  A61K47/12 ,  A61P17/06 ,  A61K47/26 ,  A61K47/14 ,  A61K47/06 ,  A61K47/32 ,  A61K47/20

CPC classification number: A61K31/05 ,  A61K9/06 ,  A61K47/44 ,  A61K47/10 ,  A61K47/183 ,  A61K47/12 ,  A61P17/06 ,  A61K47/26 ,  A61K47/14 ,  A61K47/06 ,  A61K47/32 ,  A61K47/20

Abstract: Provided herein are topical composition comprising tapinarof and combination compositions comprising a therapeutically effective dose of tapinarof and a therapeutically effective dose of at least one additional active agent, selected from at least one corticosteroid, calcipotriene, at least one JAK inhibitor and combinations thereof, and a carrier suitable for topical administration.
The above compositions are useful for the treatment, prevention or alleviation of skin disorders selected from psoriasis and atopic dermatitis and exhibit synergistic or additive effects which allow reducing the doses of the active agents in the compositions.

公开(公告)号：US20190015366A1

公开(公告)日：2019-01-17

申请号：US16033260

申请日：2018-07-12

Applicant: SOL-GEL TECHNOLOGIES LTD.

Inventor： Ofer TOLEDANO ,  Karine Neimann ,  Maya Erlich ,  Dorit Marco

IPC: A61K31/202 ,  A61K9/50 ,  A61K9/00 ,  A61K9/107 ,  A61K9/06

Abstract: The present application is directed to compositions comprising microcapsules comprising encapsulated tretinoin, wherein the microcapsule size is less than 50 μm; and to methods of use thereof.

公开(公告)号：US12133919B2

公开(公告)日：2024-11-05

申请号：US17327729

申请日：2021-05-23

Applicant: Sol-Gel Technologies Ltd.

Inventor： Ofer Toledano ,  Karine Neimann ,  Danil Finkel-Moiseev ,  Maya Erlich ,  Dorit Marco

IPC: A61K9/48 ,  A61K9/00 ,  A61K9/50 ,  A61K31/202 ,  A61K31/203 ,  A61K31/235 ,  A61K31/327 ,  A61K31/336

Abstract: The present application is directed to stabilized core-shell microcapsules comprising a core of benzoyl peroxide (BPO) or all trans retinoic acid (ATRA) and a metal-oxide shell; and to pharmaceutical compositions and methods of use thereof.

公开(公告)号：US20210361586A1

公开(公告)日：2021-11-25

申请号：US17327724

申请日：2021-05-23

Applicant: Sol-Gel Technologies Ltd.

Inventor： Ofer Toledano ,  Karine Neimann ,  Danil Finkel-Moiseev ,  Maya Erlich ,  Dorit MARCO

IPC: A61K9/50 ,  A61K31/327 ,  A61K31/203 ,  A61K9/00

Abstract: The present application is directed to stabilized core-shell microcapsules comprising a core of benzoyl peroxide (BPO) or all trans retinoic acid (ATRA) and a metal-oxide shell; and to pharmaceutical compositions and methods of use thereof.

公开(公告)号：US20210212962A1

公开(公告)日：2021-07-15

申请号：US17147602

申请日：2021-01-13

Applicant: Sol-Gel Technologies Ltd.

Inventor： Marcel Zighelboim ,  Hila Hakak Djerbi ,  Karine Neimann

IPC: A61K31/05 ,  A61K31/44 ,  A61K9/00 ,  A61K9/06 ,  A61P17/00

Abstract: The present invention, in some embodiments thereof, relates to topical compositions and methods of treatment, prevention and/or amelioration of granuloma annulare, a non-infection granulomatous disease, or a subcutaneous inflammation by topical or intralesional administration of compositions comprising tapinarof.

公开(公告)号：US11986456B2

公开(公告)日：2024-05-21

申请号：US18076444

申请日：2022-12-07

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe Arkin ,  Karine Neimann ,  Ofer Toledano

IPC: A61K31/327 ,  A61K9/00 ,  A61K9/06 ,  A61K9/10 ,  A61K9/107 ,  A61K9/50 ,  A61P17/00 ,  A61P17/10

CPC classification number: A61K31/327 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/10 ,  A61K9/107 ,  A61K9/50 ,  A61P17/00 ,  A61P17/10

Abstract: A regimen is described for the therapeutic treatment of rosacea. The regimen includes topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes from about 2.5% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The regimen achieves, in a group of such subjects, a primary measure of success of at least about 9%, at least about 25%, at least about 40%, or at least about 47%, after application of said pharmaceutical composition once daily for at least about 2 weeks, at least about 4 weeks, at least about 8 weeks, or at least about 12 weeks, respectively.

公开(公告)号：US11541026B2

公开(公告)日：2023-01-03

申请号：US17541847

申请日：2021-12-03

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe Arkin ,  Karine Neimann ,  Ofer Toledano

IPC: A61K31/327 ,  A61P17/10 ,  A61K9/00 ,  A61K9/06 ,  A61K9/107 ,  A61P17/00 ,  A61K9/50 ,  A61K9/10

Abstract: A regimen is described for the therapeutic treatment of rosacea. The regimen includes topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes from about 2.5% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The regimen achieves, in a group of such subjects, a primary measure of success of at least about 9%, at least about 25%, at least about 40%, or at least about 47%, after application of said pharmaceutical composition once daily for at least about 2 weeks, at least about 4 weeks, at least about 8 weeks, or at least about 12 weeks, respectively.